Elicera Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-14.45	-17.41	-16.11	-16.4	-19.44	-13.12
Depreciation & Amortization	-	-	0.01	0.01	0.01	0.01
Other Operating Activities	-	-	-	0	0	-
Change in Accounts Receivable	-2.31	-1.41	-	-	-	-
Change in Accounts Payable	-2.98	0.52	1.16	0.15	-1.32	0.1
Change in Other Net Operating Assets	-8.05	-3.26	-8.53	1.31	12.17	-1.28
Operating Cash Flow	-27.79	-21.55	-23.46	-14.92	-8.57	-14.29
Sale (Purchase) of Intangibles	0	0	-	-0	-	-
Investment in Securities	-0	-	-	0.48	-	-0
Investing Cash Flow	-	0	-	0.48	-	-0
Issuance of Common Stock	-	22.03	27.56	-	-	62
Other Financing Activities	-	-2.03	-7.08	-	-	-6.88
Financing Cash Flow	-0	20	20.48	-	-	55.12
Net Cash Flow	-27.79	-1.55	-2.98	-14.44	-8.57	40.83
Cash Interest Paid	0.01	0.01	0.05	0.08	0.13	0
Cash Income Tax Paid	-	-	-	-	-0	-
Levered Free Cash Flow	-22.71	-15.36	-17.94	-9.26	-1.32	-9.37
Unlevered Free Cash Flow	-22.7	-15.36	-17.91	-9.21	-1.24	-9.37
Change in Working Capital	-13.34	-4.14	-7.36	1.46	10.85	-1.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.